Nom du produit:(2-chlorophenyl)-morpholin-4-ylmethanone
IUPAC Name:4-(2-chlorobenzoyl)morpholine
- CAS：6392-26-3
- Formule moléculaire：C11H12ClNO2
- Pureté：95%+
- Numéro de catalogue：CM1075075
- Poids moléculaire：225.67
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:6392-26-3
- Formule moléculaire:C11H12ClNO2
- Point de fusion:-
- Code SMILES:ClC1=CC=CC=C1C(=O)N1CCOCC1
- Densité:
- Numéro de catalogue:CM1075075
- Poids moléculaire:225.67
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Morpholines
- Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.
- morpholine price
- if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.
Column Infos
- Tradipitant
- Vanda announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment of gastroparesis in over 40 years and to be accepted for review by the FDA for gastroparesis in over 30 years. Tradipitant is an NK-1R antagonist. It works by blocking substance P, a small signaling molecule. Tradipitant can affect gastric peristalsis and directly affect neurotransmission in the brain area responsible for nausea and vomiting, thus playing a role in the treatment of symptoms of gastroparesis. This NDA is mainly based on the results of the Phase II VP-VLY-686-2301 study and the Phase III VP-VLY-686-3301 study.
Recherche 
+86 21 5895 0110 
